Avacta Group PLC (AVCT)

London
110.00
+1.10(+0.98%)
  • Volume:
    636,112
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    110.00 - 110.00

AVCT Overview

Prev. Close
112.4
Day's Range
110-110
Revenue
6.14M
Open
111
52 wk Range
37.99-144.15
EPS
-0.096
Volume
636,112
Market Cap
294.2M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
1,398,675
P/E Ratio
-9.85
Beta
1.86
1-Year Change
-8.3%
Shares Outstanding
259,438,467
Next Earnings Date
03 Apr 2023
What is your sentiment on Avacta Group?
or
Market is currently closed. Voting is open during market hours.

Avacta Group PLC News

Avacta Group PLC Analysis

Avacta Group PLC Company Profile

Avacta Group PLC Company Profile

Employees
133

Avacta Group Plc, a clinical stage biopharmaceutical company, develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms in the United Kingdom, North America, South Korea, and rest of Asia and Europe. It operates through Diagnostics and Therapeutics segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops AffiDX SARS-CoV-2 lateral flow rapid antigen tests, as well as Affimer reagents for third party products; and novel cancer immunotherapies combining proprietary platforms. The company has a research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein alpha; drug development collaboration with LG Chem Life Sciences; partnership with Tufts University School of Medicine for developing Affimer drug conjugate therapies; licensing agreement with POINT Biopharma Inc. for the development of tumour activated radiopharmaceuticals; and drug development partnership with AffyXell to develop engineered mesenchymal stem cells to treat autoimmune diseases. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.

Read More

Analyst Price Target

Average154.95 (+40.86% Upside)
High154.949
Low154.949
Price110
No. of Analysts1
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellSell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellBuy
SummaryStrong SellStrong SellStrong SellStrong SellNeutral
  • Its all about the AVA
    0
    • Anyone else just think Avacta have had 2 years to get a test out yet how did all the Chinese tests got there a year and a half earlier?
      3
      • and how are the Chinese test kits testing for the new variants that keep coming?
        0
      • Its called “corruption”.
        0
    • Or even ********
      3
      • ETF!
        1
        • UK demand alone for 'accurate' & easy to perform rapid lateral flow tests is apparently running at c. 1.8m units/day. Thus hypothetically at say £5 each, that's a revenue run-rate (whilst schools are open) of £9m/day, or >£200m/month. Not bad news for the likes of Avacta, Omega Diagnostics & Abingdon health, along with PCR testing firms such as Novacyt & SourceBio Internationa, who should also benefit from extra 'knock-on' confirmatory volume having to be performed by their mobile/fixed labs.
          2
          • All coming speedily to fruition, with regard to the covid test’s. The cash gsnerated will fund th Ed cancer side. This will bs the major bread winner. Of course after a future Nasdaq quoute, this will most likely lead to a take out by sons big pharma. Buy now, in the next 3 weeks this share will be much higher, imo
            0
            • why such a bounce? now back to where it was 2 days ago
              0
              • FOMO Friday
                0
            • am l the only one thinks once the manufacturing details are released this will go to at least £4? With the LFT printing money every second for the next year at least, a buyback, special dividend or takeover has to be on the cards, likely the later given the start of that ava6000 cancer therapy trials.
              2
              • buy and hold...as the new spread re the tests it should boost price further.
                1
              • This will be sales of LFT test kits in the UK, then Europe and even world wide could follow, so it could go much higher, 👍
                0
            • Avacta have the best rapid antigen test going. Only one way from here...
              3
              • SP finally going down. CEO has a nice house from the sale proceeds
                5
                • CEO sold some of his holding. So? Guess he could have sold out completely if he had no faith.
                  1